Physician profile
Elizabeth Daniel
NPI 1679991954
$9,022.60
in general payments reported to CMS, 2019-2025
29 companies · $94.85 in 2025
The $94.85 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $942 · 2021: $2,294 · 2022: $3,334 · 2023: $1,986 · 2024: $77.94 · 2025: $94.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,149.60 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,298.47 | 2020-2023 | Nucala |
| Genzyme Corporation | $1,153.98 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $900.63 | 2020-2024 | Breztri, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $745.61 | 2020-2025 | Dupixent |
| Optinose US, INC. | $514.38 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $495.42 | 2020-2023 | Cuvitru, Takhzyro |
| Amgen INC. | $467.42 | 2022-2025 | Tezspire |
| Csl Behring | $434.69 | 2020-2023 | Hizentra, Haegarda |
| Pfizer INC. | $374.50 | 2020-2023 | |
| Genentech USA, INC. | $355.37 | 2020-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $325.91 | 2020-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $297.96 | 2021-2024 | |
| Kaleo, INC. | $273.67 | 2020-2023 | Auvi-Q |
| Grifols USA, LLC | $238.07 | 2021-2023 | Prolastin-C Liquid, Xembify |
| Abbvie INC. | $213.10 | 2022-2023 | Rinvoq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $193.33 | 2021-2023 | Orladeyo |
| Incyte Corporation | $187.21 | 2021-2024 | Opzelura |
| Alk-Abello, INC | $130.26 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $102.72 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $82.49 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.52 | 2020-2021 | |
| Phadia US INC. | $46.88 | 2021-2023 | Immunocap |
| Merck Sharp & Dohme LLC | $29.09 | 2021-2022 | |
| Galderma Laboratories, L.P. | $23.55 | 2025 | Nemluvio |
| Genentech, INC. | $21.59 | 2019 | |
| Hikma Pharmaceuticals USA | $18.66 | 2023 | Ryaltris |
| Horizon Therapeutics Plc | $15.92 | 2021 | |
| Blueprint Medicines Corporation | $15.34 | 2023 | Ayvakit |
| Mylan Specialty L.P. | $12.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.